Preventing adsorption of immunoglobulin G to solid surfaces using poloxamer 407 eliminates artifactual stimulation of neutrophils

Journal of Immunological Methods

Volumn 392, Issue 1-2, 2013, Pages 49-56

  Kustiawan, Iwan ^a   Derksen, Ninotska I L ^a   Rispens, Theo ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Intravenous immunoglobulin; Neutrophil activation; Poloxamer 407; Unspecific binding

Indexed keywords

DETERGENT; ELASTASE; FC RECEPTOR; IMMUNOGLOBULIN G; IONIC SURFACTANT; POLOXAMER; LEUKOCYTE ELASTASE;

ADSORPTION; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; PROTEIN BINDING; CELL INTERACTION; CRITICAL MICELLE CONCENTRATION; DRUG BINDING; GRANULOCYTE; HUMAN EXPERIMENT; MOLECULAR INTERACTION; NORMAL HUMAN; SOLID; SOLID SURFACE; SURFACE PROPERTY;

ADSORPTION; ANIMALS; CATTLE; HUMANS; IMMUNOGLOBULIN G; MICELLES; NEUTROPHILS; POLOXAMER; SURFACE PLASMON RESONANCE; SURFACE-ACTIVE AGENTS;

EID: 84880041564     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.03.009     Document Type: Article

References (24)

1. Abes R., Dutertre C.A., Agnelli L., Teillaud J.L. Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target. Expert Rev. Clin. Immunol. 2009, 5:735.
2. Andersson J., Ekdahl K.N., Lambris J.D., Nilsson B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 2005, 26:1477.
3. Barichello J.M., Morishita M., Takayama K., Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int. J. Pharm. 1999, 184:189.
4. Bouchemal K., Agnely F., Koffi A., Ponchel G. A concise analysis of the effect of temperature and propanediol-1, 2 on Pluronic F127 micellization using isothermal titration microcalorimetry. J. Colloid Interface Sci. 2009, 338:169.
5. Dumortier G., Grossiord J.L., Agnely F., Chaumeil J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 2006, 23:2709.
6. Escobar-Chavez J.J., Lopez-Cervantes M., Naik A., Kalia Y.N., Quintanar-Guerrero D., Ganem-Quintanar A. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J. Pharm. Pharm. Sci. 2006, 9:339.
7. Giacomelli C.E., Norde W. Influence of hydrophobic Teflon particles on the structure of amyloid beta-peptide. Biomacromolecules 2003, 4:1719.
8. Giacomelli C.E., Norde W. Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces. Macromol. Biosci. 2005, 5:401.
9. Higurashi S., Machino Y., Suzuki E., Suzuki M., Kohroki J., Masuho Y. Both the Fab and Fc domains of IgG are essential for ROS emission from TNF-alpha-primed neutrophils by IVIG. Biochem. Biophys. Res. Commun. 2012, 417:794.
10. Jamur M.C., Oliver C. Permeabilization of cell membranes. Methods Mol. Biol. 2010, 588:63.
11. Kao P., Parhi P., Krishnan A., Noh H., Haider W., Tadigadapa S., Allara D.L., Vogler E.A. Volumetric interpretation of protein adsorption: interfacial packing of protein adsorbed to hydrophobic surfaces from surface-saturating solution concentrations. Biomaterials 2011, 32:969.
12. Katakam M., Banga A.K. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm. Dev. Technol. 1997, 2:143.
13. Korkmaz B., Horwitz M.S., Jenne D.E., Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol. Rev. 2010, 62:726.
14. Kuhnert P., Schalch L., Jungi T.W. Cytokine induction in human mononuclear cells stimulated by IgG-coated culture surfaces and by IgG for infusion. Clin. Immunol. Immunopathol. 1990, 57:218.
15. Liao F., Shin H.S., Rhee S.G. Tyrosine phosphorylation of phospholipase C-gamma 1 induced by cross-linking of the high-affinity or low-affinity Fc receptor for IgG in U937 cells. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:3659.
16. Ohki K., Amano F., Yamamoto S., Kohashi O. Suppressive effects of serum on the LPS-induced production of nitric oxide and TNF-alpha by a macrophage-like cell line, WEHI-3, are dependent on the structure of polysaccharide chains in LPS. Immunol. Cell Biol. 1999, 77:143.
17. Parkins D.A., Lashmar U.T. The formulation of biopharmaceutical products. Pharm. Sci. Technol. Today 2000, 3:129.
18. Roitt I., Brostoff J., Male D. Immunology 1996, Mosby Publications, London, England. 4th ed.
19. Shalel S., Streichman S., Marmur A. The mechanism of hemolysis by surfactants: effect of solution composition. J. Colloid Interface Sci. 2002, 252:66.
20. Singh-Joy S.D., McLain V.C. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int. J. Toxicol. 2008, 27(Suppl. 2):93.
21. Teeling J.L., De Groot E.R., Eerenberg A.J., Bleeker W.K., Van M.G., Aarden L.A., Hack C.E. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin. Exp. Immunol. 1998, 114:264.
22. Verhoeven A.J., van Schaik M.L., Roos D., Weening R.S. Detection of carriers of the autosomal form of chronic granulomatous disease. Blood 1988, 71:505.
23. Vogt R.F., Phillips D.L., Henderson L.O., Whitfield W., Spierto F.W. Quantitative differences among various proteins as blocking agents for ELISA microtiter plates. J. Immunol. Methods 1987, 101:43.
24. Wedege E., Svenneby G. Effects of the blocking agents bovine serum albumin and Tween 20 in different buffers on immunoblotting of brain proteins and marker proteins. J. Immunol. Methods 1986, 88:233.